Here's something you might be interested in.
Ask a Hipster — Advice you didn't know you needed
Big Screen — Movie commentary
Blurt — Music's inside track
Booze News — San Diego spirits
Classical Music — Immortal beauty
Classifieds — Free and easy
Cover Stories — Front-page features
Drinks All Around — Bartenders' drink recipes
Excerpts — Literary and spiritual excerpts
Feast! — Food & drink reviews
Feature Stories — Local news & stories
Fishing Report — What’s getting hooked from ship and shore
From the Archives — Spotlight on the past
Golden Dreams — Talk of the town
The Gonzo Report — Making the musical scene, or at least reporting from it
Letters — Our inbox
Movies@Home — Local movie buffs share favorites
Movie Reviews — Our critics' picks and pans
Musician Interviews — Up close with local artists
Neighborhood News from Stringers — Hyperlocal news
News Ticker — News & politics
Obermeyer — San Diego politics illustrated
Outdoors — Weekly changes in flora and fauna
Overheard in San Diego — Eavesdropping illustrated
Poetry — The old and the new
Reader Travel — Travel section built by travelers
Reading — The hunt for intellectuals
Roam-O-Rama — SoCal's best hiking/biking trails
San Diego Beer — Inside San Diego suds
SD on the QT — Almost factual news
Sheep and Goats — Places of worship
Special Issues — The best of
Street Style — San Diego streets have style
Surf Diego — Real stories from those braving the waves
Theater — On stage in San Diego this week
Tin Fork — Silver spoon alternative
Under the Radar — Matt Potter's undercover work
Unforgettable — Long-ago San Diego
Unreal Estate — San Diego's priciest pads
Your Week — Daily event picks
Sort of like the results of a fad diet
Stock value of Orexigen rises and falls based on news of weight-loss drug
Stock of San Diego biotech Orexigen Therapeutics, which produces a weight-loss product, Contrave, has had a full ride in a short time. The Food and Drug Administration (FDA) is irate over the company's release of information from a testing procedure for possible cardiac side effects of Contrave.
A Food and Drug Administration official has told Forbes magazine that the information released by Orexigen was probably "unreliable," "misleading," and "likely false." The company could face fines, civil penalties, and even the withdrawal of Contrave from the market.
On Monday, March 2, Orexigen stock closed at $5.79. On Tuesday, the company, in patent and Securities and Exchange Commission filings, stated that Contrave actually reduced the risk of heart attacks and cardiovascular problems. The stock zoomed, and by Wednesday, March 4, was up to $8.49. After the tongue-lashing by the FDA official, the stock dropped 5.65 percent today, and then another 17.48 percent in after-hours trading, down to $6.61. Now, investors are nervous over Orexigen's breaking of protocol requiring that interim analysis data must remain confidential, even within a company.
The case may be reminiscent of a 2009 misadventure by another local biotech, Sequenom. The company hyped its prenatal test for Down syndrome. But investigations revealed the company's testing procedures were flawed. The chief executive was fired, as was Elizabeth Dragon, senior vice president of research and development, and several other top executives. Dragon was charged by the Securities and Exchange Commission with lying to the public about the Down syndrome tests's accuracy. She died in 2011. The company settled a $14 million shareholder suit.
Note: In mid-February, Don Bauder entered the intensive-care ward of a hospital with a severe case of flu and pneumonia. After four days there, he spent five days in other hospital rooms. He wishes to thank all those who sent him messages. He may be convalescing for another month. He will resume submitting items regularly when he has fully recovered.
Here's something you might be interested in.
Sort of like the results of a fad diet
Stock value of Orexigen rises and falls based on news of weight-loss drug
Sort of like the results of a fad diet
Stock value of Orexigen rises and falls based on news of weight-loss drug
Stock of San Diego biotech Orexigen Therapeutics, which produces a weight-loss product, Contrave, has had a full ride in a short time. The Food and Drug Administration (FDA) is irate over the company's release of information from a testing procedure for possible cardiac side effects of Contrave.
A Food and Drug Administration official has told Forbes magazine that the information released by Orexigen was probably "unreliable," "misleading," and "likely false." The company could face fines, civil penalties, and even the withdrawal of Contrave from the market.
On Monday, March 2, Orexigen stock closed at $5.79. On Tuesday, the company, in patent and Securities and Exchange Commission filings, stated that Contrave actually reduced the risk of heart attacks and cardiovascular problems. The stock zoomed, and by Wednesday, March 4, was up to $8.49. After the tongue-lashing by the FDA official, the stock dropped 5.65 percent today, and then another 17.48 percent in after-hours trading, down to $6.61. Now, investors are nervous over Orexigen's breaking of protocol requiring that interim analysis data must remain confidential, even within a company.
The case may be reminiscent of a 2009 misadventure by another local biotech, Sequenom. The company hyped its prenatal test for Down syndrome. But investigations revealed the company's testing procedures were flawed. The chief executive was fired, as was Elizabeth Dragon, senior vice president of research and development, and several other top executives. Dragon was charged by the Securities and Exchange Commission with lying to the public about the Down syndrome tests's accuracy. She died in 2011. The company settled a $14 million shareholder suit.
Note: In mid-February, Don Bauder entered the intensive-care ward of a hospital with a severe case of flu and pneumonia. After four days there, he spent five days in other hospital rooms. He wishes to thank all those who sent him messages. He may be convalescing for another month. He will resume submitting items regularly when he has fully recovered.
Comments